AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27528460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol, clinical symptoms, and genetic variation (NR3C1 and NR3C2)
Number of subjects: 0
Study 27528460 — intervention group
Group type: EXPERIMENTAL
Intervention: NR3C1 genetic variation
Number of subjects: 0
Study 27528460 — intervention group
Group type: EXPERIMENTAL
Intervention: NR3C2 genetic variation
Number of subjects: 0
Study 27528460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 0
Study 27528526 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based coaching
Number of subjects: 0
Study 27528526 — intervention group
Group type: COMPARATOR
Intervention: Phone-based coaching
Number of subjects: 0
Study 27528724 — intervention group
Group type: EXPERIMENTAL
Intervention: AM0010 (Pegylated Recombinant Human Interleukin-10) at doses of 1 to 40 μg/kg once per day, self-administered subcutaneously.
Number of subjects: 51
Study 27529227 — intervention group
Group type: EXPERIMENTAL
Intervention: DIoB assay for immunophenotyping
Number of subjects: 0
Study 27529227 — intervention group
Group type: EXPERIMENTAL
Intervention: DIoB assay for immune monitoring
Number of subjects: 0
Study 27529295 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 277
Study 27529295 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk fat, waist, and BMI
Number of subjects: 277
Study 27529295 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body DXA scan
Number of subjects: 277
Study 27529295 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 277
Study 27530401 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection through interviews and focus groups
Number of subjects: 2099
Study 27530401 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial insecurity
Number of subjects: 2099
Study 27530413 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary reconstruction
Number of subjects: 552
Study 27530413 — intervention group
Group type: COMPARATOR
Intervention: Revision reconstruction
Number of subjects: 552
Study 27530528 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly postal and online antibiotic prescription feedback over 24 months
Number of subjects: 2900
Study 27530528 — intervention group
Group type: COMPARATOR
Intervention: No information provided
Number of subjects: 2900
Study 27530601 — intervention group
Group type: EXPERIMENTAL
Intervention: pREset stent retriever
Number of subjects: 100
Study 27530601 — intervention group
Group type: COMPARATOR
Intervention: Directly Admitted Patients (DAP)
Number of subjects: 100
Study 27530601 — intervention group
Group type: COMPARATOR
Intervention: Transferred Patients (TP)
Number of subjects: 100
Study 27530601 — intervention group
Group type: COMPARATOR
Intervention: Transfer status
Number of subjects: 100
Study 27530601 — intervention group
Group type: COMPARATOR
Intervention: Occlusion time
Number of subjects: 100
Study 27530735 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure
Number of subjects: 0
Study 27530939 — intervention group
Group type: EXPERIMENTAL
Intervention: Northern hospitals
Number of subjects: 115
Study 27530939 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern hospitals
Number of subjects: 115
Study 27530939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary hospitals
Number of subjects: 115
Study 27530939 — intervention group
Group type: EXPERIMENTAL
Intervention: Provincial-level hospitals
Number of subjects: 115
Study 27531181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 0
Study 27531346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Atrial Fibrillation
Number of subjects: 1192
Study 27531346 — intervention group
Group type: COMPARATOR
Intervention: Paroxysmal Atrial Fibrillation
Number of subjects: 1192
Study 27531525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 0
Study 27531554 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor
Number of subjects: 41
Study 27531554 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 41
Study 27531554 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating free DNA (cfDNA)
Number of subjects: 41
Study 27531554 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Number of subjects: 41
Study 27531679 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide (25 mg/day orally on days 1-21 of each cycle) and dexamethasone (40 mg/week)
Number of subjects: 45
Study 27531679 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/dexamethasone
Number of subjects: 45
Study 27531735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 623
Study 27531735 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use, depression, psychological distress
Number of subjects: 623
Study 27531735 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of pregnancy intentions
Number of subjects: 623
Study 27532019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (VEM) 960 mg twice daily for 6 weeks followed by Ipilimumab (IPI) 10 mg/kg every 3 weeks for 4 doses (induction), then every 12 weeks (maintenance) until disease progression or unacceptable toxicity
Number of subjects: 46
Study 27532019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (VEM) at previously tolerated dose after progression on IPI
Number of subjects: 46
Study 27532019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (VEM) followed by Ipilimumab (IPI)
Number of subjects: 46
Study 27532020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated chemoradiation
Number of subjects: 0
Study 27532020 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionated chemoradiation
Number of subjects: 0
Study 27532363 — intervention group
Group type: EXPERIMENTAL
Intervention: HHHFNC at 4 to 6 L/min
Number of subjects: 316
Study 27532363 — intervention group
Group type: COMPARATOR
Intervention: nCPAP/BiPAP at 4 to 6 cm H2O
Number of subjects: 316
Study 27532363 — intervention group
Group type: EXPERIMENTAL
Intervention: HHHFNC
Number of subjects: 316
Study 27532363 — intervention group
Group type: COMPARATOR
Intervention: nCPAP/BiPAP
Number of subjects: 316
Study 27532364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg oral daily) plus Everolimus (10 mg oral daily)
Number of subjects: 541
Study 27532364 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (25 mg oral daily) plus Placebo
Number of subjects: 541
Study 27532364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus Everolimus
Number of subjects: 541
Study 27533787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid (200 mg once daily for 6 days)
Number of subjects: 0
Study 27533787 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily for 10 days)
Number of subjects: 0
Study 27533991 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 783
Study 27533991 — intervention group
Group type: COMPARATOR
Intervention: No Coronary Angiography (CA)
Number of subjects: 783
Study 27534260 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour sensor glucose concentrations in free-living conditions
Number of subjects: 111
Study 27534260 — intervention group
Group type: EXPERIMENTAL
Intervention: Median sensor glucose concentration
Number of subjects: 111
Study 27534260 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with fasting plasma glucose concentrations
Number of subjects: 111
Study 27534260 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with serum insulin concentrations
Number of subjects: 111
Study 27534260 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with HOMA-IR
Number of subjects: 111
Study 27534260 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic area under the curve (AUC)
Number of subjects: 111
Study 27534643 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cysteine
Number of subjects: 508
Study 27534643 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cysteinylglycine
Number of subjects: 508
Study 27534643 — intervention group
Group type: COMPARATOR
Intervention: Cysteine and cysteinylglycine
Number of subjects: 508
Study 27535544 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive data base of high quality clinical and molecular data
Number of subjects: 3000
Study 27535544 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth molecular characterization
Number of subjects: 3000
Study 27535544 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily assessments and long-term follow-up
Number of subjects: 3000
Study 27535663 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor 240 μg/kg administered subcutaneously every other day from day +2 until day +21 or until neutrophil recovery
Number of subjects: 30
Study 27535663 — intervention group
Group type: COMPARATOR
Intervention: Control group (95 allogeneic peripheral blood stem cell transplant recipients)
Number of subjects: 30
Study 27535748 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofosfamide (120 mg/m2 to 340 mg/m2) administered one week before chemoradiotherapy and repeated weekly up to six doses.
Number of subjects: 0
Study 27535748 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofosfamide in combination with neo-adjuvant chemoradiotherapy.
Number of subjects: 0
Study 27535872 — intervention group
Group type: EXPERIMENTAL
Intervention: High education
Number of subjects: 100
Study 27535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study 27536380 — intervention group
Group type: EXPERIMENTAL
Intervention: PATE (Parents as Teachers curriculum enhanced with a nutrition and lifestyle behavior curriculum)
Number of subjects: 82
Study 27536380 — intervention group
Group type: COMPARATOR
Intervention: PAT (Parents as Teachers curriculum only)
Number of subjects: 82
Study 27536421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (A/V) 10/160 mg
Number of subjects: 90
Study 27536421 — intervention group
Group type: COMPARATOR
Intervention: Losartan/hydrochlorothiazide (L/H) 100/25 mg
Number of subjects: 90
Study 27536422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 52 weeks
Number of subjects: 226
Study 27536422 — intervention group
Group type: COMPARATOR
Intervention: Metformin for 52 weeks (active control)
Number of subjects: 226
Study 27536431 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC aliskiren 300/amlodipine 10
Number of subjects: 187
Study 27536436 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 12
Study 27536436 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 12
Study 27536436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27536436 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (1 mg/kg and 10 mg/kg)
Number of subjects: 12
Study 27536437 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast added to ICS + LABA for 4 weeks
Number of subjects: 17
Study 27536442 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat HCl 50 mg
Number of subjects: 14
Study 27536442 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat HCl 150 mg
Number of subjects: 14
Study 27536442 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat HCl 450 mg
Number of subjects: 14
Study 27536442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27536449 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER 40-120 mg/day
Number of subjects: 355
Study 27536449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 27536452 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine oral solution (OS) 5 mg
Number of subjects: 2
Study 27536452 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine dry syrup (DS) 10 mg
Number of subjects: 2
Study 27536459 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 0.1 mg dutasteride capsules
Number of subjects: 36
Study 27536459 — intervention group
Group type: COMPARATOR
Intervention: 1 × 0.5 mg dutasteride capsule
Number of subjects: 36
Study 27536708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of rituximab
Number of subjects: 0
Study 27536938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 29
Study 27536938 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 29
Study 27536938 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedure abstinence recommendations
Number of subjects: 29
Study 27537328 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet lower in sodium, protein, and acid precursors, supplemented with water for 4 weeks
Number of subjects: 12
Study 27537786 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (up to 40 mg/kg/d)
Number of subjects: 46
Study 27538197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoarterial (BA) ratio measurement
Number of subjects: 106
Study 27538197 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of BA ratio with lung function
Number of subjects: 106
Study 27538433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-risk MDS (IPSS low and intermediate-1 risk)
Number of subjects: 1500
Study 27538433 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk MDS (IPSS intermediate-2 and high risk)
Number of subjects: 1500
Study 27538433 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUS
Number of subjects: 1500
Study 27538433 — intervention group
Group type: EXPERIMENTAL
Intervention: AML
Number of subjects: 1500
Study 27538433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue substudy
Number of subjects: 1500
Study 27538433 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported health-related quality of life
Number of subjects: 1500
Study 27538465 — intervention group
Group type: EXPERIMENTAL
Intervention: Panagen (tablet form of fragmented human DNA preparation)
Number of subjects: 80
Study 27538465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27538465 — intervention group
Group type: EXPERIMENTAL
Intervention: Panagen
Number of subjects: 80
Study 27539172 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-business eating pattern
Number of subjects: 4082
Study 27539172 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 4082
Study 27539301 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-β PET imaging
Number of subjects: 178
Study 27539301 — intervention group
Group type: COMPARATOR
Intervention: Cognitively healthy stroke survivors
Number of subjects: 178
Study 27539301 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-MCI patients
Number of subjects: 178
Study 27540019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroid (ICS) treatment
Number of subjects: 170
Study 27540019 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation (elevated IL-6 or hsCRP)
Number of subjects: 170
Study 27540019 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 comorbidities
Number of subjects: 170
Study 27540019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ICS
Number of subjects: 170
Study 27540363 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice-daily
Number of subjects: 15
Study 27540466 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 0
Study 27540466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27541029 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative diagnosis by the surgeon
Number of subjects: 131
Study 27541029 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics
Number of subjects: 131
Study 27541029 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological confirmation of appendicitis
Number of subjects: 131
Study 27541373 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 454
Study 27541373 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 454
Study 27541380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day)
Number of subjects: 122
Study 27542133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation (FMT) from healthy donors
Number of subjects: 19
Study 27542325 — intervention group
Group type: EXPERIMENTAL
Intervention: bant2 mobile app intervention in addition to standard of care
Number of subjects: 150
Study 27542325 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 150
Study 27542789 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 mm Lotus valve
Number of subjects: 110
Study 27542789 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mm Lotus valve
Number of subjects: 110
Study 27542789 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mm Lotus valve
Number of subjects: 110
Study 27542789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVI with the repositionable Lotus valve
Number of subjects: 110
Study 27542843 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD-6™ lung function testing
Number of subjects: 227
Study 27543317 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-related text messages
Number of subjects: 82
Study 27543317 — intervention group
Group type: COMPARATOR
Intervention: Text messages unrelated to SB
Number of subjects: 82
Study 27543526 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive beat-to-beat Nexfin finger BP (BPfin)
Number of subjects: 25
Study 27543531 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPOC scores (>80)
Number of subjects: 267
Study 27543531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate SPOC scores (41-80)
Number of subjects: 267
Study 27543531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SPOC scores (≤40)
Number of subjects: 267
Study 27543531 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of SPOC scores to regression model
Number of subjects: 267
Study 27543601 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR2-ADC (BAY 1187982)
Number of subjects: 0
Study 27543800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging (used in 38% of cases)
Number of subjects: 619
Study 27543800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (36% of imaging cases)
Number of subjects: 619
Study 27543800 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (3% of imaging cases)
Number of subjects: 619
Study 27543800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both imaging modalities (1.45% of imaging cases)
Number of subjects: 619
Study 27544054 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (20 μg)
Number of subjects: 60
Study 27544054 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (100 μg)
Number of subjects: 60
Study 27544054 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (500 μg)
Number of subjects: 60
Study 27544054 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (all doses)
Number of subjects: 60
Study 27544283 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH+ intervention
Number of subjects: 0
Study 27544327 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (without lacquer cracks)
Number of subjects: 32
Study 27544327 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (with lacquer cracks)
Number of subjects: 32
Study 27544377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 120
Study 27544377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27544832 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 461
Study 27544832 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea indices
Number of subjects: 461
Study 27544832 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily energy expenditure (DEE)
Number of subjects: 461
Study 27544832 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopenia (OP) prevalence
Number of subjects: 461
Study 27544832 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis (OS) prevalence
Number of subjects: 461
Study 27545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time behaviour
Number of subjects: 0
Study 27545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 0
Study 27546069 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 195
Study 27547173 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and contingency management treatment
Number of subjects: 81
Study 27547422 — intervention group
Group type: COMPARATOR
Intervention: Short-term intensive insulin therapy (IIT) for 2-4 weeks (basal detemir, bolus aspart) followed by placebo therapy for 48 weeks
Number of subjects: 25
Study 27547431 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of older patients to the ICON-1 study
Number of subjects: 300
Study 27547431 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of age between those able to consent and those unable to consent
Number of subjects: 300
Study 27547431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in participation
Number of subjects: 300
Study 27547429 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (selective endothelin A receptor antagonist)
Number of subjects: 23
Study 27547429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27548475 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 concentration in subjects with delayed enhancement (DE)
Number of subjects: 61
Study 27548475 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 concentration in subjects without delayed enhancement (DE)
Number of subjects: 61
Study 27548475 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between myocardial fibrosis and Gal-3 concentration
Number of subjects: 61
Study 27548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory avoiding behaviors
Number of subjects: 77
Study 27548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory seeking behaviors
Number of subjects: 77